Gabapentin Capsule
Product Images NDC 70518-4411

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 70518-4411). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Gabapentin Capsule 300 mg label for 90 capsules, oral dosage form. The label indicates the capsules are yellow and brown. The product is repackaged by RemedyRepack Inc., Indiana, PA. Manufacturer listed as ACI Healthcare USA, Inc., Coral Springs, FL. Storage instructions and safety warnings are also included on the label.*

FDA Label Image

Formula (Ab1e0185 B802 4cf2 A5d4 B71f27f1dcb0 00)

A formula illustrating creatinine clearance calculation, showing the relationship between age, weight, serum creatinine, and a multiplication factor for female patients. It is typically used to estimate kidney function.*

FDA Label Image

Figure1 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 01)

Chemical structure of Gabapentin showing a cyclohexane ring bonded to an amino group (CH2NH2) and a carboxyl group (CH2CO2H).*

FDA Label Image

Image 1 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 02)

A line graph showing mean pain score over 8 weeks comparing placebo and Gabapentin at 3600 mg/day. The x-axis represents weeks from baseline to week 8, and the y-axis represents mean pain score from 0 to 10. The graph includes a labeled 4-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

Image 2 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 03)

Line graph depicting mean pain scores over a 7-week period comparing placebo, gabapentin 1800 mg/day, and gabapentin 2400 mg/day. The x-axis represents weeks including baseline, with annotations for a 3-week dose titration period followed by a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10, illustrating a decrease in pain scores for gabapentin groups compared to placebo over time.*

FDA Label Image

Image 3 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 04)

A bar graph titled "Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies" comparing response rates in two studies. Study 1 compares placebo (PBO) at 12% to Gabapentin (GBP) 3600 mg at 29%. Study 2 compares placebo at 14% to Gabapentin 1800 mg at 32% and 2400 mg at 34%. Statistical significance is indicated by p-values (p<0.01, p<0.001).*

FDA Label Image

Image 4 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 05)

A scatter plot showing the percentage difference versus daily dose in mg for Gabapentin from three studies labeled as Study a, Study b, and Study c. The x-axis represents daily doses ranging from 600 mg to 1800 mg, and the y-axis displays the percentage difference ranging from 2% to 22%. Data points for each study are distinctly marked, with Study a in black squares, Study b in gray squares, and Study c in white squares, each showing increasing differences with higher doses.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.